We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
Cap. Flow
-$118M
Cap. Flow %
-3.94%
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$40.3M
2
ARGX icon
argenx
ARGX
+$39.9M
3
RVMD icon
Revolution Medicines
RVMD
+$39.2M
4
IMVT icon
Immunovant
IMVT
+$29.2M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$16.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.3M
2
VIR icon
Vir Biotechnology
VIR
+$48M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$46.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$35.7M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
51
DELISTED
Astria Therapeutics
ATXS
$16.3M 0.54%
2,189,462
– –
VRDN icon
52
Viridian Therapeutics
VRDN
$2.74B
$15.5M 0.52%
1,011,205
-765,181
-43% -$14.6M
AORT icon
53
Artivion
AORT
$1.29B
$14.1M 0.47%
931,352
– –
ESTA icon
54
Establishment Labs
ESTA
$2.15B
$13.6M 0.45%
277,683
-147,241
-35% -$8.8M
EOLS icon
55
Evolus
EOLS
$592M
$13.6M 0.45%
+1,485,801
New +$13.3M
TCMD icon
56
Tactile Systems Technology
TCMD
$534M
$9.94M 0.33%
707,159
+104,782
+17% +$2.05M
BMEA icon
57
Biomea Fusion
BMEA
$125M
$9.86M 0.33%
716,441
– –
LONA
58
LeonaBio Inc
LONA
$75.5M
$9.69M 0.32%
479,728
– –
NTRA icon
59
Natera
NTRA
$48.5B
$9.65M 0.32%
218,178
-187,091
-46% -$9.54M
ZYME icon
60
Zymeworks
ZYME
$1.96B
$9.17M 0.31%
1,446,123
-970,109
-40% -$7.16M
SLDB icon
61
Solid Biosciences
SLDB
$1.06B
$8.81M 0.29%
3,495,933
– –
RYTM icon
62
Rhythm Pharmaceuticals
RYTM
$7.8B
$8.73M 0.29%
+380,828
New +$8.53M
CMAX
63
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$8.11M 0.27%
127,452
+205
+0.2% +$14.4K
PRTA icon
64
Prothena Corp
PRTA
$484M
$7.99M 0.27%
165,615
-19,000
-10% -$1.13M
OM icon
65
Outset Medical
OM
$80.8M
$7.2M 0.24%
44,132
-16,025
-27% -$3.78M
FUSN
66
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$7.15M 0.24%
2,751,395
– –
LABP
67
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$5.77M 0.19%
1,486,991
– –
AKRO
68
CALL
DELISTED
Akero Therapeutics
AKRO
$5.46M 0.18%
+800,000
New +$37.2M
TERN
69
DELISTED
Terns Pharmaceuticals
TERN
$5.41M 0.18%
+1,075,000
New +$6.82M
TYRA icon
70
Tyra Biosciences
TYRA
$1.59B
$4.96M 0.17%
360,000
– –
NBTX
71
Nanobiotix
NBTX
$2.11B
$4.86M 0.16%
555,066
-504,734
-48% -$4.19M
AXGN icon
72
Axogen
AXGN
$2.68B
$4.38M 0.15%
875,898
-588,924
-40% -$4.08M
NVNO
73
enVVeno Medical
NVNO
$7.5M
$4.21M 0.14%
22,332
– –
XFOR icon
74
X4 Pharmaceuticals
XFOR
$412M
$3.86M 0.13%
118,182
– –
NVAX icon
75
PUT
Novavax
NVAX
$1.56B
$3.77M 0.13%
+1,300,000
New +$10.4M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $118M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.

  • Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
  • Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
  • Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
  • Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
  • Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
  • Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.